MindBio Therapeutics Corp. MBIO
CNSX
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -11.25% | 104.50% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -11.25% | 100.01% | |||
| Operating Income | 11.25% | -100.01% | |||
| Income Before Tax | 9.79% | -100.67% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 9.79% | -100.67% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 500.00% | -66.67% | |||
| Net Income | 9.94% | -100.66% | |||
| EBIT | 11.25% | -100.01% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 83.47% | -16.77% | |||
| Normalized Basic EPS | 83.48% | -16.77% | |||
| EPS Diluted | 83.47% | -16.77% | |||
| Normalized Diluted EPS | 54.84% | 57.30% | |||
| Average Basic Shares Outstanding | 444.92% | 71.83% | |||
| Average Diluted Shares Outstanding | 99.27% | 369.89% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||